AXA IM Alts, a global leader in alternative investments with €183bn of assets under management, announces the launch of a Global Health Strategy following a $200m cornerstone commitment from AXA Group, as it builds on its existing offering in the sector. The Strategy is actively managed without reference to any benchmark.
The Strategy focuses specifically on four core areas of innovation: medical devices, biopharmaceuticals, vaccines, and diagnostics and on investments into healthcare companies that are in late-clinical and/or early commercial stages, which represent a key inflection point of a company’s organic growth trajectory.
Targeting total commitments of up to $500 million (over €440 million), the Strategy seeks investments in companies aiming to deliver healthcare solutions at accessible price points for global markets, including high volume markets, where demand for new products continues to benefit from rapid growth in healthcare spending and population growth. Global healthcare spending grew 30% faster than global GDP from 2010 to 2017, with the rate twice as fast in middle income versus high income economies. Additionally, there is a significant funding gap in global healthcare, further fuelling investment opportunities and the potential for attractive relative value.
Read more: Press Release
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.